肝癌肝移植手术前后靶向及免疫治疗的指征及时机探讨

肝移植是治疗早期肝细胞癌（肝癌）的重要措施之一，肝癌肝移植术后复发严重影响了受者的长期生存率。靶向及免疫治疗在降低肝癌分期、控制疾病进展、降低复发率、延长寿命及改善生活质量等方面均发挥了重要作用，然而靶向及免疫治疗在肝癌肝移植受者中的使用目前仍未形成共识，包括靶向及免疫治疗使用的指征、时机及剂量等。本文对肝癌肝移植手术前后靶向及免疫治疗的指征及时机等展开综述，阐述相关临床进展，旨在为改善肝癌肝移植受者的生存提供参考。

Discussion on the indications and timing of targeted therapy and immunotherapy before and after liver transplantation for hepatocellular carcinoma

Liver transplantation is one of the main treatments of early hepatocellular carcinoma (HCC). The recurrence of HCC after liver transplantation severely affects the long-term survival rate of the recipients. Targeted therapy and immunotherapy play a critical role in HCC downstaging, preventing disease progression, reducing recurrence rate, prolonging the survival and improving the quality of life. However, no consensus has been reached on the application of targeted therapy and immunotherapy in recipients undergoing liver transplantation for HCC, including indications, timing and dosage. In this article, clinical research progresses on the indications and timing of targeted therapy and immunotherapy before and after liver transplantation for HCC were reviewed, aiming to provide reference for prolonging the survival of recipients after liver transplantation for HCC.